Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

The Endothelial Barrier Is not Rate-limiting to Insulin Action in the Myocardium of Male Mice.

Sanwal R, Khosraviani N, Advani SL, Advani A, Lee WL.

Endocrinology. 2020 Apr 1;161(4). pii: bqaa029. doi: 10.1210/endocr/bqaa029.

PMID:
32103251
2.

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.

Connelly KA, Zhang Y, Desjardins JF, Nghiem L, Visram A, Batchu SN, Yerra VG, Kabir G, Thai K, Advani A, Gilbert RE.

Cardiovasc Diabetol. 2020 Feb 8;19(1):13. doi: 10.1186/s12933-020-0994-y.

3.

Distinctive and common features of moderate aplastic anaemia.

Patel BJ, Barot SV, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, Maciejewski JP.

Br J Haematol. 2020 Jan 31. doi: 10.1111/bjh.16460. [Epub ahead of print]

PMID:
32004386
4.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.

Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS.

Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.

5.

Real-Time Automated Hazard Detection Framework for Health Information Technology Systems.

Omitaomu OA, Ozmen O, Olama MM, Pullum LL, Kuruganti T, Nutaro J, Klasky HB, Zandi H, Advani A, Laurio AL, Ward M, Scott J, Nebeker JR.

Health Syst (Basingstoke). 2019 May 7;8(3):190-202. doi: 10.1080/20476965.2019.1599701. eCollection 2019.

PMID:
31839931
6.

Navigating the nexus of MRD and novel agents in ALL.

Advani AS, Copelan EA.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):9-16. doi: 10.1182/hematology.2019000008.

PMID:
31808877
7.

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.

Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H.

Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.

8.

Positioning time in range in diabetes management.

Advani A.

Diabetologia. 2020 Feb;63(2):242-252. doi: 10.1007/s00125-019-05027-0. Epub 2019 Nov 7. Review.

PMID:
31701199
9.

Development of a Drug Information Service Collaborative in Academia.

Kim J, Hoover R, Perkins S, Advani A.

Ann Pharmacother. 2020 Mar;54(3):287-289. doi: 10.1177/1060028019884079. Epub 2019 Oct 18.

PMID:
31625410
10.

The treatment of adolescents and young adults with acute lymphoblastic leukemia.

Advani AS, Hanna R.

Leuk Lymphoma. 2020 Jan;61(1):18-26. doi: 10.1080/10428194.2019.1658103. Epub 2019 Aug 27.

PMID:
31452423
11.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22. Review.

PMID:
31446198
12.

Genomics of therapy-related myeloid neoplasms.

Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T.

Haematologica. 2020 Mar;105(3):e98-e101. doi: 10.3324/haematol.2019.219352. Epub 2019 Aug 14. No abstract available.

13.

Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease.

Majumder S, Hadden MJ, Thieme K, Batchu SN, Niveditha D, Chowdhury S, Yerra VG, Advani SL, Bowskill BB, Liu Y, Vakili H, Alghamdi TA, White KE, Geldenhuys L, Siddiqi FS, Advani A.

Diabetologia. 2019 Nov;62(11):2129-2142. doi: 10.1007/s00125-019-4967-1. Epub 2019 Aug 9.

PMID:
31399844
14.

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.

Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, Maciejewski JP, Carew JS.

Leukemia. 2019 Dec;33(12):2971-2974. doi: 10.1038/s41375-019-0529-2. Epub 2019 Jul 29. No abstract available.

PMID:
31358855
15.

The 3i Conceptual Framework for Recognizing Patient Perspectives of Type 1 Diabetes During Emerging Adulthood.

Markowitz B, Pritlove C, Mukerji G, Lavery JV, Parsons JA, Advani A.

JAMA Netw Open. 2019 Jul 3;2(7):e196944. doi: 10.1001/jamanetworkopen.2019.6944.

16.

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.

Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B.

J Natl Compr Canc Netw. 2019 May 1;17(5):414-423. doi: 10.6004/jnccn.2019.0024.

PMID:
31085755
17.

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729. doi: 10.1016/j.bbmt.2019.04.020. Epub 2019 Apr 27.

18.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski J, Unger A, Kalaycio M, de Lima M, Sekeres MA.

Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.

19.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

20.

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.

Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, Thai K, Gilbert RE.

JACC Basic Transl Sci. 2019 Feb 25;4(1):27-37. doi: 10.1016/j.jacbts.2018.11.010. eCollection 2019 Feb.

21.

Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI.

Am J Kidney Dis. 2019 Jun;73(6):786-796. doi: 10.1053/j.ajkd.2018.12.034. Epub 2019 Feb 22.

PMID:
30799029
22.

Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Singh SK, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI.

Diabetes Obes Metab. 2019 Jun;21(6):1388-1398. doi: 10.1111/dom.13665. Epub 2019 Mar 28.

PMID:
30761725
23.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.

PMID:
30658992
24.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Apr;94(4):408-416. doi: 10.1002/ajh.25394. Epub 2019 Jan 17.

PMID:
30623490
25.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes.

Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A.

Leuk Lymphoma. 2019 Jun;60(6):1587-1590. doi: 10.1080/10428194.2018.1543885. Epub 2019 Jan 8. No abstract available.

PMID:
30618304
26.

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

de Haas V, Ismaila N, Advani A, Arber DA, Dabney RS, Patel-Donelly D, Kitlas E, Pieters R, Pui CH, Sweet K, Zhang L.

J Clin Oncol. 2019 Jan 20;37(3):239-253. doi: 10.1200/JCO.18.01468. Epub 2018 Dec 3. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

27.

Methods to identify linear network models: a review.

Advani A, Malde B.

Swiss J Econ Stat. 2018;154(1):12. doi: 10.1186/s41937-017-0011-x. Epub 2018 Feb 5.

28.

Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.

Sawalha Y, Advani AS.

Int J Hematol Oncol. 2018 Apr 10;7(1):IJH02. doi: 10.2217/ijh-2017-0023. eCollection 2018 Mar. Review.

29.

Histone H3 Serine 10 Phosphorylation Facilitates Endothelial Activation in Diabetic Kidney Disease.

Alghamdi TA, Batchu SN, Hadden MJ, Yerra VG, Liu Y, Bowskill BB, Advani SL, Geldenhuys L, Siddiqi FS, Majumder S, Advani A.

Diabetes. 2018 Dec;67(12):2668-2681. doi: 10.2337/db18-0124. Epub 2018 Sep 13.

30.

Histone Deacetylase Inhibitors and Diabetic Kidney Disease.

Hadden MJ, Advani A.

Int J Mol Sci. 2018 Sep 5;19(9). pii: E2630. doi: 10.3390/ijms19092630. Review.

31.

The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca2+ Flux and Phosphoinositide 3-Kinase γ.

Batchu SN, Thieme K, Zadeh FH, Alghamdi TA, Yerra VG, Hadden MJ, Majumder S, Kabir MG, Bowskill BB, Ladha D, Gramolini AO, Connelly KA, Advani A.

Diabetes. 2018 Nov;67(11):2443-2455. doi: 10.2337/db18-0410. Epub 2018 Aug 27.

32.

Novel Therapies in Acute Lymphoblastic Leukemia.

Phelan KW, Advani AS.

Curr Hematol Malig Rep. 2018 Aug;13(4):289-299. doi: 10.1007/s11899-018-0457-7. Review.

PMID:
30078158
33.

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Shah B, DeAngelo DJ, Freyer DR, Douer D, Johnson RH, Hayes-Lattin B, Lewis M, Jaboin JJ, Coccia PF, Bleyer A.

Am J Hematol. 2018 Oct;93(10):1254-1266. doi: 10.1002/ajh.25229. Epub 2018 Sep 3. Review.

34.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.

35.

Histones and heart failure in diabetes.

Yerra VG, Advani A.

Cell Mol Life Sci. 2018 Sep;75(17):3193-3213. doi: 10.1007/s00018-018-2857-1. Epub 2018 Jun 22. Review.

36.

Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation.

Bugyei-Twum A, Ford C, Civitarese R, Seegobin J, Advani SL, Desjardins JF, Kabir G, Zhang Y, Mitchell M, Switzer J, Thai K, Shen V, Abadeh A, Singh KK, Billia F, Advani A, Gilbert RE, Connelly KA.

Cardiovasc Res. 2018 Oct 1;114(12):1629-1641. doi: 10.1093/cvr/cvy131.

37.

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA.

Blood. 2018 Jun 21;131(25):2782-2788. doi: 10.1182/blood-2018-01-826693. Epub 2018 Apr 4.

38.

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.

Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer A.

JAMA Oncol. 2018 May 1;4(5):725-734. doi: 10.1001/jamaoncol.2017.5305. Review.

PMID:
29450465
39.

HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.

Brijmohan AS, Batchu SN, Majumder S, Alghamdi TA, Thieme K, McGaugh S, Liu Y, Advani SL, Bowskill BB, Kabir MG, Geldenhuys L, Siddiqi FS, Advani A.

Front Pharmacol. 2018 Feb 1;9:34. doi: 10.3389/fphar.2018.00034. eCollection 2018.

40.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

41.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

42.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

43.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

44.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
45.

Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease.

Majumder S, Thieme K, Batchu SN, Alghamdi TA, Bowskill BB, Kabir MG, Liu Y, Advani SL, White KE, Geldenhuys L, Tennankore KK, Poyah P, Siddiqi FS, Advani A.

J Clin Invest. 2018 Jan 2;128(1):483-499. doi: 10.1172/JCI95946. Epub 2017 Dec 11.

46.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

47.

Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y, Bjornstad P, Lai V, Tse J, Cham L, Majumder S, Bowskill BB, Kabir MG, Advani SL, Gibson IW, Sood MM, Advani A, Cherney DZI.

Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F412-F422. doi: 10.1152/ajprenal.00445.2017. Epub 2017 Nov 15.

48.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
49.

Acute lymphoblastic leukemia (ALL).

Advani A.

Best Pract Res Clin Haematol. 2017 Sep;30(3):173-174. doi: 10.1016/j.beha.2017.07.004. Epub 2017 Jul 11. No abstract available.

PMID:
29050689
50.

"MOR" engineering of antibodies in ALL.

Advani AS.

Blood. 2017 Sep 28;130(13):1487-1488. doi: 10.1182/blood-2017-07-797126. No abstract available.

PMID:
28963104

Supplemental Content

Loading ...
Support Center